SureTrader Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 7/27/2016 12:46:44 AM - Followers: 832 - Board type: Free - Posts Today: 3

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/21/2016 11:47:37 AM
ELTP News: Current Report Filing (8-k) 07/21/2016 07:16:35 AM
ELTP News: Friendable, Inc. (OTC Pink: FDBL) – Ramps Up Infrastructure To Accommodate Growth 07/19/2016 08:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/15/2016 05:27:18 PM
ELTP News: Current Report Filing (8-k) 07/15/2016 05:26:22 PM
#217429  Sticky Note Here is the TRUTH about T-max-SEC-Filed! Drugdoctor 07/25/16 06:43:08 AM
#207474  Sticky Note These people cannot be help by the FDA lasers 06/24/16 06:10:52 PM
#207005  Sticky Note For new investors who want to learn more Dr_Thorfin 06/22/16 10:14:38 AM
#203141  Sticky Note How Pharma Copes with the Pain of Developing Moose45 06/06/16 08:11:20 AM
#200119  Sticky Note Dear WeeZuhl, WeeZuhl 05/15/16 10:56:35 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#218018   Easily the greatest omen, by far, was the 30thirdwart 07/27/16 12:46:44 AM
#218017   WOW good job helping the shorts!!Broke .18 moving down!!!! tmeier 07/27/16 12:35:07 AM
#218016   You know those two you mentioned took the captainsjg 07/27/16 12:09:19 AM
#218015   Why hatefulness? You like to watch people take Dubster watching 07/26/16 11:59:33 PM
#218014   Many more have left than that. At BostonTrader 07/26/16 11:51:13 PM
#218013   Just like no2coolaid and Weezul have left jtf3 07/26/16 11:47:43 PM
#218012   Instead of the same tired answer over and BostonTrader 07/26/16 11:46:42 PM
#218011   It's not game over yet. Pending talks Aqua 07/26/16 11:45:21 PM
#218010   Don't you think if it was such a jtf3 07/26/16 11:33:32 PM
#218009   Perhaps, but where was Hakim's A game for dr_lowenstein 07/26/16 11:23:46 PM
#218008   Either 4-6-cents is a generous gift. For Aqua 07/26/16 11:11:12 PM
#218007   We are close to 6 cents, if you jtf3 07/26/16 10:35:46 PM
#218006   * * $ELTP Video Chart 07-26-16 * * ClayTrader 07/26/16 10:22:21 PM
#218005   LMAO; yeah heard the same BS at .06 Couch 07/26/16 10:20:52 PM
#218004 John_Langston 07/26/16 10:16:01 PM
#218003   I hear you John. The only thing BostonTrader 07/26/16 10:07:27 PM
#218002   I agree with your reply about Gene. He Couch 07/26/16 09:32:41 PM
#218001   I heard the same BS when the stock Couch 07/26/16 09:26:17 PM
#218000   John can you please post the buy sell Drunk Joe 07/26/16 09:17:38 PM
#217999   I was watching L2 and three heavy buyers captainsjg 07/26/16 09:05:20 PM
#217998   All the best to you. Hope you do well. minnie21 07/26/16 09:04:38 PM
#217997   Really strong support at .15 John_Langston 07/26/16 09:02:10 PM
#217996   Haha ya they did. L2 was pretty crazy captainsjg 07/26/16 09:00:18 PM
#217995   I will say this if I was a captainsjg 07/26/16 08:58:44 PM
#217994   I like watching the MMs trying to dance John_Langston 07/26/16 08:58:31 PM
#217993   I will buy more, because I think it John_Langston 07/26/16 08:55:48 PM
#217992   I agree with your reply about Gene. He minnie21 07/26/16 08:51:35 PM
#217991   You could be right. Total unknown. Traders and captainsjg 07/26/16 08:47:15 PM
#217990   Savvy ELTP investors know this too, shall pass. minnie21 07/26/16 08:46:12 PM
#217989   I think this trades lower and settles around John_Langston 07/26/16 08:43:38 PM
#217988   Just checking in. See the slow bleed is captainsjg 07/26/16 08:41:00 PM
#217987   This isn't any different. John_Langston 07/26/16 08:01:39 PM
#217986   LMFAO; that was BS at .05 cents when Couch 07/26/16 07:57:01 PM
#217985   Wow, ELTP is going bankrupt? namtae 07/26/16 07:53:16 PM
#217984   And I was told that the company would Couch 07/26/16 07:49:29 PM
#217983   On the bright side, it closed 7/10ths of John_Langston 07/26/16 07:48:35 PM
#217982   I said it at 57¢. Couch 07/26/16 07:46:09 PM
#217981   Yep that is all. Couch 07/26/16 07:43:53 PM
#217980   The collapse of ELTP may have lots more namtae 07/26/16 07:43:47 PM
#217979   I know if you don't sell you don't lose John_Langston 07/26/16 07:43:06 PM
#217978   Such a terrible generalization. That's okay. I'll be Couch 07/26/16 07:42:16 PM
#217976   my opinion is today's sell volume was from John_Langston 07/26/16 07:40:29 PM
#217975   October is payday month. We sat at .17 Couch 07/26/16 07:39:41 PM
#217974   Guess we just have to agree to disagree. Couch 07/26/16 07:37:28 PM
#217973   biotech, pharma stocks most down John_Langston 07/26/16 07:37:18 PM
#217972   Guaranteed!!!! BostonTrader 07/26/16 07:35:53 PM
#217971   today's sell volume is less than 1% of John_Langston 07/26/16 07:35:27 PM
#217970   Great question........whoever has written the script will choose Couch 07/26/16 07:33:26 PM
#217969   I'm not chasing a downward spiral. John_Langston 07/26/16 07:30:31 PM
#217968   I heard the CRL was GOOD news and John_Langston 07/26/16 07:28:34 PM